Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in neutrophils | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4643
Sealed predictions
- CHD7 in oligodendrocytes, braak-0.18 (p 0.651) → +0.26 (p 0.493)receipt 4650
- CHD7 in dopamine neurons, braak-0.32 (p 0.402) → +0.45 (p 0.222)receipt 4651
Swarm cases
receipt 4651: CHD7 in dopamine neurons, braak
- power
- full sample -0.03 (p 0.901, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.956, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.06 (p 0.807, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.12, sign flips 4; without severely affected donors -0.03 (p 0.901, n 18). fragile.
- cell type
- strongest in OPCs: +0.60 (p 0.0083, n 18) vs -0.03 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CHD7 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CHD7 · OPCs · braak: substantia nigra, an independent cohort (already registered)
receipt 4650: CHD7 in oligodendrocytes, braak
- power
- full sample +0.06 (p 0.807, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.03 (p 0.922, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.08 (p 0.754, n 18). could be the mix.
- skeptic
- leave-one-out range -0.07 to +0.16, sign flips 4; without severely affected donors +0.06 (p 0.807, n 18). fragile.
- cell type
- strongest in OPCs: +0.60 (p 0.0083, n 18) vs +0.06 in oligodendrocytes. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CHD7 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CHD7 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.25 p 0.374 (needs p < 4.3e-4)
Receipts
loading the receipts